Mechanism, cost, access and what the data means
Vilks K, Videja M, Makrecka-Kuka M, Katkevics M, Sevostjanovs E, Grandane A, et al
Conclusion: Investor Implications Hims' mess warns health stock chasers
N Engl J Med 383:14251435 McMurray JJV, Solomon SD, Inzucchi SE, Kber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Blohlvek J, Bhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukt A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, OMeara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjstrand M, Langkilde AM (2019) DAPA-HF Trial Committees and Investigators
How does Ipamorelin compare to CJC-1295